middle.news
Imagion Biosystems Advances MagSense® HER2 Amid $1.66M Half-Year Loss and $3.5M Capital Raise
1:13am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
Imagion Biosystems Advances MagSense® HER2 Amid $1.66M Half-Year Loss and $3.5M Capital Raise
1:13am on Saturday 30th of August, 2025 AEST
Key Points
Half-year loss increased slightly to $1.66 million
Manufacturing of MagSense® HER2 Imaging Agent initiated for Phase 2 trial
FDA pre-IND feedback received, IND submission planned for late 2025
Key clinical advisors and principal investigator appointed
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
IMAGION BIOSYSTEMS (ASX:IBX)
OPEN ARTICLE